

**UNCLASSIFIED**

**Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Army** **Date:** March 2023

<b>Appropriation/Budget Activity</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army / BA 2: Applied Research</i>	<b>R-1 Program Element (Number/Name)</b> PE 0602115A / <i>Biomedical Technology</i>
--	--

COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	11.489	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	11.489
EB2: <i>HIV Biomedical Technology</i>	-	11.489	-	-	-	-	-	-	-	-	0.000	11.489

**A. Mission Description and Budget Item Justification**

This Program Element (PE) funds the Military Human Immunodeficiency Virus (HIV) Research Program and the Combatting Antimicrobial Resistant Bacteria (CARB) projects. The goal of the Military HIV Research Program is to refine identification methods for determining genetic diversity of the virus, to conduct preclinical work in laboratory animals including non-human primates to identify candidates for global HIV-1 vaccine, and to evaluate and prepare overseas sites for clinical trials with these vaccine candidates. For the CARB program, funding provides for the development of strategies to prevent, mitigate, and treat antibiotic resistant bacteria in wounds through the CARB - Walter Reed Army Institute of Research (WRAIR) Discovery and Wound Program.

<b>B. Program Change Summary (\$ in Millions)</b>	<b>FY 2022</b>	<b>FY 2023</b>	<b>FY 2024 Base</b>	<b>FY 2024 OCO</b>	<b>FY 2024 Total</b>
Previous President's Budget	11.925	0.000	0.000	-	0.000
Current President's Budget	11.489	0.000	0.000	-	0.000
Total Adjustments	-0.436	0.000	0.000	-	0.000
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-0.436	-			
• SBIR/STTR Transfer	-	-			

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2024 Army										<b>Date:</b> March 2023		
<b>Appropriation/Budget Activity</b> 2040 / 2					<b>R-1 Program Element (Number/Name)</b> PE 0602115A / <i>Biomedical Technology</i>				<b>Project (Number/Name)</b> EB2 / <i>HIV Biomedical Technology</i>			
<b>COST (\$ in Millions)</b>	<b>Prior Years</b>	<b>FY 2022</b>	<b>FY 2023</b>	<b>FY 2024 Base</b>	<b>FY 2024 OCO</b>	<b>FY 2024 Total</b>	<b>FY 2025</b>	<b>FY 2026</b>	<b>FY 2027</b>	<b>FY 2028</b>	<b>Cost To Complete</b>	<b>Total Cost</b>
EB2: <i>HIV Biomedical Technology</i>	-	11.489	-	-	-	-	-	-	-	-	0.000	11.489

**A. Mission Description and Budget Item Justification**

The Military Human Immunodeficiency Virus (HIV) Research Program conducts research on HIV, which causes acquired immunodeficiency syndrome (AIDS). Work in this area includes refining improved identification methods to determine genetic diversity of the virus and evaluating and preparing overseas sites for clinical trials with global vaccine candidates. Additional activities include refining candidate vaccines for preventing HIV and undertaking preclinical studies (studies required before testing in humans) to assess vaccine for potential to protect and/or manage the disease in infected individuals. This project is jointly managed through an Interagency Agreement between United States Army Medical Research and Development Command (USAMRDC) and the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

The Combatting Antimicrobial Resistant Bacteria (CARB) research program was established in response to Presidential direction in late 2013 to create a National Strategy to address the critical issue of antimicrobial resistance. This effort's focus is on the development of new/novel antibiotics, especially those targeting the most resistant and worrisome Gram negative bacterial pathogens, using existing expertise at the Walter Reed Army Institute of Research (WRAIR), and leveraging other WRAIR capabilities to evaluate viable candidate targets for advanced discovery. This project supports (both directly and indirectly) Global Health Security Agenda priorities to respond rapidly and effectively to biological threats of international concern.

The cited work is also consistent with the Under Secretary of Defense, Research and Engineering Science and Technology focus areas, and supports the principal area of Military Relevant Infectious Diseases to include HIV.

**B. Accomplishments/Planned Programs (\$ in Millions)**

	<b>FY 2022</b>	<b>FY 2023</b>	<b>FY 2024</b>
<p><b>Title:</b> HIV Biomedical Technology</p> <p><b>Description:</b> The Military HIV Research Program (MHRP) conducts research on HIV, which causes AIDS. Work in this area includes refining improved identification methods to determine genetic diversity of the virus and evaluating and preparing overseas sites for future vaccine trials. Additional activities include refining candidate vaccines for preventing HIV and undertaking preclinical studies (studies required before testing in humans) to assess vaccine for potential to protect and/or manage the disease in infected individuals.</p>	9.536	-	-
<p><b>Title:</b> Combatting Antimicrobial Resistant Bacteria</p> <p><b>Description:</b> The CARB research program focus is to establish in-house capabilities for an antibacterial drug discovery program directed toward military relevant drug-resistant bacteria that a) encompasses assessment of external products/candidates/leads that may meet Department of Defense (DoD) requirements, b) opens active intramural based discovery efforts of new potential products/candidates/leads for development, and c) fosters partnerships with external collaborators to develop/co-develop new potential antibacterial treatment therapeutics.</p>	1.953	-	-

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2024 Army Date: March 2023

<b>Appropriation/Budget Activity</b> 2040 / 2	<b>R-1 Program Element (Number/Name)</b> PE 0602115A / <i>Biomedical Technology</i>	<b>Project (Number/Name)</b> EB2 / <i>HIV Biomedical Technology</i>
--	--	--

<b>B. Accomplishments/Planned Programs (\$ in Millions)</b>	<b>FY 2022</b>	<b>FY 2023</b>	<b>FY 2024</b>
<b>Accomplishments/Planned Programs Subtotals</b>	11.489	-	-

**C. Other Program Funding Summary (\$ in Millions)**

N/A

**Remarks**

**D. Acquisition Strategy**

N/A